Advertisement

Ads Placeholder
Loading...

Probiotec Limited

PBP.AXASX
Healthcare
Drug Manufacturers - Specialty & Generic
$2.98
$-0.01(-0.33%)
Australian Market opens in 63h 34m

Probiotec Limited (PBP.AX) Stock Competitors & Peer Comparison

See (PBP.AX) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
PBP.AXA$2.98-0.33%242.3M29.80A$0.10+3.61%
CAU.AXA$0.54+0.00%300.5M-16.88-A$0.03N/A
AFP.AXA$2.73+0.00%286.3M21.00A$0.13+0.61%
LV1.AXA$0.92+0.00%144.1M3.05A$0.30N/A
VLS.AXA$2.52+1.61%134.3M13.97A$0.18+5.57%
ANP.AXA$0.06-4.92%52.3M-2.90-A$0.02N/A
SNT.AXA$0.03+3.23%50.7M-3.10-A$0.01N/A
MVP.AXA$0.39+5.41%43.9M-1.15-A$0.34N/A
NXS.AXA$0.15+0.00%42.4M-2.90-A$0.05+100.00%
LGP.AXA$0.10+5.32%29.7M4.85A$0.02N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

PBP.AX vs CAU.AX Comparison April 2026

PBP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PBP.AX stands at 242.3M. In comparison, CAU.AX has a market cap of 300.5M. Regarding current trading prices, PBP.AX is priced at A$2.98, while CAU.AX trades at A$0.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PBP.AX currently has a P/E ratio of 29.80, whereas CAU.AX's P/E ratio is -16.88. In terms of profitability, PBP.AX's ROE is +0.13%, compared to CAU.AX's ROE of +0.34%. Regarding short-term risk, PBP.AX is less volatile compared to CAU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PBP.AX.Check CAU.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions